Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Infectious disease antibodies bind viral envelope proteins or bacterial toxins for neutralization and infection studies. Sotrovimab, casirivimab and bamlanivimab bind the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Palivizumab and nirsevimab neutralize respiratory syncytial virus (RSV) by binding its fusion protein. Bezlotoxumab binds Clostridioides difficile toxin B, while raxibacumab and obiltoxaximab neutralize the protective antigen of anthrax toxin. Further antibodies target human immunodeficiency virus (HIV), influenza, hepatitis B virus and Ebola virus glycoproteins, as well as cytomegalovirus and BK virus.
Siltartoxatug is a human monoclonal antibody of the IgG1κ subtype, specifically designed to target tetanus toxin. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.
Synonyms: MAPP-66
MB-66 (MAPP-66) is a fully human IgG1 monoclonal antibody designed for vaginal application, specifically targeting HSV (Herpes Simplex Virus) and HIV (Human Immunodeficiency Virus). This product is presented as a monoclonal antibody film, optimizing local delivery and bioavailability at the site of viral entry. For experimental controls, MB-66 utilizes Human IgG1 kappa as its isotype control, ensuring specificity and reliability in research applications.
Exbivirumab is a monoclonal antibody specifically targeting the hepatitis B virus (HBV). This antibody is designed to augment the antiviral efficacy of hepatitis B immunoglobulin (HBIG), providing a potentiated response against HBV infections. Exbivirumab is pivotal in research focused on the development of more effective therapeutic protocols for hepatitis B, offering a promising tool for both basic research and clinical applications.
Synonyms: MHAB5553A; RG70026
Lesofavumab (MHAB5553A) is a humanized IgG1κ monoclonal antibody specifically targeting the influenza B virus. This antibody is designed for high specificity and affinity in binding to influenza B antigens, making it an essential tool for research focused on viral pathogenesis, immune response, and potential therapeutic interventions for influenza B infections.
Synonyms: anti-hepatitis B; OST 577; SDZ-OST 577
Tuvirumab (OST 577; SDZ-OST 577) is a monoclonal antibody of the human IgG1 subclass, specifically targeting the hepatitis B virus surface antigen (HBsAg). It binds with high specificity and affinity, exhibiting a dissociation constant (Kd) of 3.6 nM for HBsAg. This antibody is primarily utilized in the study of chronic hepatitis B, offering significant potential for research applications in this area.
Synonyms: HuVTm1.1; TMA-15
Urtoxazumab (TMA-15) is a humanized monoclonal antibody specifically targeting Shiga toxin 2 (Stx2). This antibody is designed to neutralize Stx2, a potent toxin produced by certain pathogenic strains of bacteria, thereby mitigating its effects in various biological and pathological processes. Urtoxazumab is utilized primarily in research focused on bacterial infections, particularly those involving Shiga toxin-producing organisms, and is instrumental in studying the mechanisms of toxin-induced cellular damage and the evaluation of therapeutic interventions.
Synonyms: ABthrax
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody that targets the protective antigen (PA) of Bacillus anthracis. By binding to PA, Raxibacumab effectively inhibits the interaction of the antigen with its cellular receptors, preventing the entry and subsequent toxic effects of the anthrax toxin within host cells. This antibody is utilized primarily in research focused on anthrax prevention and therapy, offering a critical tool for studying the mechanisms of anthrax toxicity and the development of countermeasures.
Setoxaximab is a chimeric humanized antibody of the IgG1-κ isotype, specifically designed to target Shiga toxin type 1. This monoclonal antibody binds with high specificity and affinity to the toxin, potentially neutralizing its effects, which is crucial in studying bacterial pathogenesis and developing therapeutic strategies against Shiga toxin-producing bacterial infections.
Synonyms: REGN-15160
Gorivitug is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.
Synonyms: NPC-21; EV2038
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ monoclonal antibody designed to target human cytomegalovirus (hCMV). This antibody exhibits its neutralizing activity by specifically binding to antigenic domain 1 of glycoprotein B, which is located on the envelope of hCMV. Through this targeted interaction, Fiztasovimab effectively inhibits the cell-to-cell transmission of the virus, providing a crucial tool for research into viral pathogenesis and therapeutic intervention strategies.
Verzistobart is a monoclonal antibody of the IgG1κ class, specifically designed to bind to the hepatitis A virus cellular receptor, HAVCR2. This targeted interaction is crucial for research focused on the pathogenesis and therapeutic interventions of hepatitis A, providing a valuable tool for both in vitro and in vivo studies.
Canrivitug is a human IgG1 λ2 monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control.
Timcevibart is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.
VRC-01 is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the gp120 envelope glycoprotein of HIV-1. This antibody inhibits viral entry into host cells by emulating the binding mechanism of the CD4 receptor with the HIV-1 gp120 envelope glycoprotein, thereby blocking the virus's ability to infect cells. For experimental control purposes, Human IgG1 kappa, Isotype Control, is recommended. VRC-01 serves as a critical tool in the study of HIV pathogenesis and the development of therapeutic strategies against HIV infection.
Rivabazumab is a recombinant monoclonal antibody specifically targeting the PcrV protein of Pseudomonas aeruginosa. This antibody is designed for the precise detection and neutralization of the PcrV component, which plays a critical role in the pathogenicity of Pseudomonas aeruginosa by facilitating the injection of toxic effector proteins into host cells. Rivabazumab is utilized extensively in research focused on bacterial infection mechanisms, vaccine development, and therapeutic interventions against Pseudomonas aeruginosa.
Synonyms: MEDI-524
Motavizumab (MEDI-524) is a monoclonal antibody targeted against the human Respiratory Syncytial Virus (RSV). This antibody is specifically designed for research into the prevention and treatment of RSV infections in high-risk infant populations. Motavizumab binds to the F protein of RSV, neutralizing the virus and potentially preventing the viral fusion with host cell membranes, a key step in the viral infection process. This makes it an invaluable tool for studies aimed at understanding and mitigating RSV pathogenesis in susceptible infant groups.
Synonyms: MEDI8897
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody designed to target and neutralize human respiratory syncytial virus (RSV). This antibody exhibits potent neutralizing activity against both RSV A and RSV B strains, demonstrated by IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab is an essential tool for research focused on respiratory infections caused by RSV, facilitating the study of virus-host interactions and the evaluation of preventive therapies.
Porgaviximab is a monoclonal antibody designed for the study of Ebola virus infections. This antibody targets specific antigens associated with the Ebola virus, making it a valuable tool for researchers investigating the pathogenesis, immune response, and potential therapeutic interventions for this deadly virus. Porgaviximab is suitable for use in a variety of experimental setups, including viral neutralization assays and immunohistochemistry studies.
Vecantoxatug is a humanized monoclonal antibody designed to target the Clostridium tetani toxin (TeNT, neurotoxin). By specifically binding to this toxin, Vecantoxatug inhibits its interaction with cellular receptors, effectively neutralizing its toxic effects. This antibody is particularly valuable for research focused on tetanus, offering potential insights into toxin mechanism and therapeutic interventions.
Synonyms: COVI-AMG; STI-2020
Plutavimab is a human IgG1-κ monoclonal antibody specifically designed to target the receptor-binding domain (RBD) of the Spike (S) glycoprotein of SARS-CoV-2. This antibody binds with high specificity and affinity, potentially neutralizing the virus by preventing its entry into host cells. Plutavimab is suitable for research applications focused on the study of viral entry mechanisms, virus-host interactions, and the development of therapeutic strategies against SARS-CoV-2.
Synonyms: HFB-30132A
Enuzovimab (HFB-30132A) is a monoclonal antibody specifically developed to target the SARS-CoV-2 Omicron variant. It exhibits high-affinity binding to the spike (S) protein of the virus, offering potential utility in therapeutic interventions against this strain.
Rivabazumab pegol is a pegylated Fab monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa. This antibody is specifically designed for the investigation of chronic infections caused by Pseudomonas aeruginosa, offering a valuable tool for research in microbial pathogenesis and host-pathogen interactions during the persistent phases of this infection. Rivabazumab pegol's unique structure and specificity make it ideal for studies focused on the development and evaluation of therapeutic strategies against this challenging bacterial pathogen.
Synonyms: XVR011
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody engineered for potent neutralization of SARS-CoV-2. This antibody exhibits broad coverage and high stability, and features silenced Fc effector functions, making it highly effective against the disease caused by SARS-CoV-2. Its design and functionality make it an essential tool for research into COVID-19 therapies and mechanisms of viral neutralization.
Synonyms: ALX-0171; VR-465
Gontivimab (ALX-0171; VR-465) is a potent nanobody targeting the respiratory syncytial virus (RSV) prefusion F protein, exhibiting a dissociation constant (K_D) of 0.113 nM. This high-affinity binding is indicative of its robust antiviral properties. Gontivimab has demonstrated efficacy in reducing viral load in both nasal and pulmonary tissues, highlighting its potential for therapeutic applications in RSV infections.
Synonyms: VIR-3434
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody specifically targeting the hepatitis B virus (HBV) surface antigen (HBsAg). Demonstrating potent in vitro neutralization capabilities, Tobevibart effectively inhibits HBsAg across all HBV genotypes and blocks viral entry for both HBV and the hepatitis delta virus (HDV). For experimental control purposes, the use of Human IgG1 lambda1 Isotype Control is recommended.
